Navigation Links
Isis Initiates Clinical Trial of CRP Drug
Date:8/13/2008

Reduction of CRP with ISIS 353512 could provide therapeutic benefit in

cardiovascular, renal and inflammatory diseases

CARLSBAD, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today it has initiated a Phase 1 study of ISIS 353512, an antisense drug that inhibits the production of C-reactive protein (CRP). CRP levels are frequently elevated in patients with a variety of diseases including cardiovascular disease, Crohn's disease, rheumatoid arthritis and end-stage renal disease. The Phase 1 study of ISIS 353512 is a blinded, randomized, placebo-controlled, dose-escalation study designed to assess the safety and pharmacokinetic profile of ISIS 353512 as well as to assess the initial effects of the drug on baseline CRP levels in healthy volunteers. In addition, Isis is designing a broad Phase 2 program to investigate multiple indications for ISIS 353512.

"We believe that CRP plays an important causal role not only in cardiovascular disease but also in renal and inflammatory diseases. Based on our preclinical data, and the safety and pharmacological data we will obtain from this study, we plan to create a Phase 2 development plan that evaluates several of the most scientifically and commercially attractive indications for ISIS 353512," said Stanley Crooke, Chairman and Chief Executive Officer of Isis. "CRP is an excellent example of the power of our technology which enables us to efficiently develop drugs to any target and to select targets that provide the most significant therapeutic benefit in disease areas where new treatment options are desperately needed."

ISIS 353512 Targets CRP

ISIS 353512 is an antisense drug that targets CRP. For many years, CRP
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
2. Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156
3. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
4. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
7. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
8. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
9. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
10. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
11. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014  Aethlon Medical, Inc. ... definitive agreement to raise approximately $3.3 million at a ... made by one institutional healthcare focused investor. Each unit consists ... a common share purchase warrant. Each whole warrant entitles ... price of $0.30 for a period of five years ...
(Date:11/26/2014)...   Regulus Therapeutics Inc . (NASDAQ: ... development of innovative medicines targeting microRNAs, today announced that ... of Regulus, will present a company overview at the ... the New York Palace Hotel on Wednesday, December 3, ... webcast at the time of the presentation and can ...
(Date:11/26/2014)... -- BioScrip ® , Inc. (NASDAQ: BIOS ) announced today ... will present at the Bank of America Merrill Lynch 2014 Leveraged ... , , , Wednesday, December 3, 2014 , , , ... , , Location: , , , Boca Raton Resort and Club, ... BioScrip, Inc. is a leading national provider of ...
Breaking Medicine Technology:Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3
... -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: ... in the development, manufacturing, and marketing of branded and ... Mr. Hong Zhao, a highly regarded executive in the ... sales and marketing, effective February 12, 2011. ...
... Calif., Feb. 10, 2011 Renaissance Surgical Arts at Newport ... center in the Western United States to offer intraoperative radiotherapy ... in the TARGIT-A multicenter human clinical trial that demonstrated IORT ... with early breast cancer. IORT has the ...
Cached Medicine Technology:Simcere Pharmaceutical Group Appoints Industry Veteran Mr. Hong Zhao as Executive Vice President of Sales and Marketing 2Renaissance Surgical Arts at Newport Harbor Announces Single-Dose Radiation Treatment Alternative for Women with Early Breast Cancer 2Renaissance Surgical Arts at Newport Harbor Announces Single-Dose Radiation Treatment Alternative for Women with Early Breast Cancer 3
(Date:11/27/2014)... Ethane Web Technologies, which is an ... reputation management service. , The company has designed ... world of internet marketing and algorithms of major search ... Web Technologies does not work with the same strategy ... to reach a conclusion what will work for the ...
(Date:11/27/2014)... 2014 VeloReality Inc. President Gary ... Life Videos (RLVs) of world-famous velo courses for the company's ... as other popular indoor velo trainers. Two dozen additional Real ... the end of November -- in time for the ... of rides in the VeloReality collection to over sixty. , ...
(Date:11/27/2014)... November 27, 2014 Serious Buyer, Andrew ... 1969 Jimi Hendrix Tuscaloosa Memorial Coliseum concert posters. Between ... played at the University of Alabama. Jimi Hendrix started ... Hawley, “It started with Gary Weinberger who was a ... University Programs Council. The council was responsible for bringing ...
(Date:11/26/2014)... CA (PRWEB) November 26, 2014 Dr. ... treat themselves this holiday season! With Parsa Mohebi Hair ... 10% off of their next FUE procedure, making it ... , FUE—which stands for “Follicular Unit Extraction”—is an advanced ... over traditional “strip” Follicular Unit Transplantation (FUT). FUE, unlike ...
(Date:11/26/2014)... 27, 2014 Sweetdressy.com, the well-known wedding ... newest selection of cheap prom dresses for ladies worldwide. ... The prom dresses from Sweetdressy.com are very popular in ... the website of Sweetdressy.com now. , Sweetdressy.com believes ... that offering the best items and best services. The ...
Breaking Medicine News(10 mins):Health News:Ethane Web Technologies Announces Online Reputation Management Service 2Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 2Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 3Health News:Serious Buyer Announces His Search For Vintage 1969 Jimi Hendrix Tuscaloosa Memorial Coliseum Concert Posters 2Health News:FUE Special at Parsa Mohebi Hair Restoration This Holiday Season 2Health News:Cheap Prom Dresses For Ladies Introduced At SweetDressy.com 2
... May 8 (HealthDay News) -- People at risk for celiac ... they show no symptoms, a new study suggests. Celiac ... small intestine when the person consumes gluten, a protein found ... with the disease has grown rapidly in recent decades, but, ...
... , MONDAY, May 9 (HealthDay News) -- Some ... emotional reactions to everyday situations, a combination that appears ... a Massachusetts General Hospital study that included 83 participants ... deficient emotional self-regulation (DESR), 33 with neither condition -- ...
... of U.S. children taken to hospital emergency departments (EDs) for ... ease worried parents, concerns. Yet true traumatic brain injury is ... minor blunt head trauma, led by Children,s Hospital Boston and ... reduce the use of head CT by as much as ...
... UK,s betting shops are attracting a new type of ... terms of problem gambling, argues initial research findings funded ... Betting shops today are virtually unrecognisable compared to the ... Act. "Under the Act, the newly licensed betting offices ...
... -- (May 9, 2011) In the wild, mammals survive ... shadowy bushes. That ability translates to the human ... in an image of our messy and stuffed suitcases. We ... our car keys on that cluttered shelf next to the ...
... patient without common symptoms of celiac disease is accurately ... study from the Beth Israel Deaconess Medical Center in ... divided the cases of nearly 800 adult patients with ... per capita earnings. Some patients had complained of acute ...
Cached Medicine News:Health News:More People May Benefit From Going Gluten-Free 2Health News:ADHD With Poor Emotional Control Seems to Run in Families 2Health News:Large study finds CT scans are frequently unnecessary after head injury in children 2Health News:Large study finds CT scans are frequently unnecessary after head injury in children 3Health News:50 years on, UK betting shops lure new breed of punters 2Health News:The brain performs visual search near optimally 2
... Korchek Technologies CareChek ... employs barcode technology, Windows ... with integrated scanners (to ... at the bedside) and ...
... Korchek Technologies CareChek Rx ... barcode technology, Windows CE ... integrated scanners (to perform ... the bedside) and an ...
... care management tools that support the nursing ... vital signs and I&O information at the ... on-line flow sheets. This design supports compliance ... the hall, or at the nursing station, ...
For superior bar code scanning performance with maximum user comfort at a highly attractive price, the LS 4000i Scanner Series from Symbol Technologies establishes an award-winning standard of excell...
Medicine Products: